p53 mutations in human lung tumors - PubMed (original) (raw)
. 1992 Apr 1;52(7):1695-8.
Affiliations
- PMID: 1312896
p53 mutations in human lung tumors
C W Miller et al. Cancer Res. 1992.
Abstract
Mutation of one p53 allele and loss of the normal p53 allele [loss of heterozygosity (LOH)] occur in many tumors including lung cancers. These alterations apparently contribute to development of cancer by interfering with the tumor suppressor activity of p53. We directly sequenced amplified DNA in the mutational hot spots (exons 4-8) of p53 in DNA samples from 40 lung cancers. Most (31 of 40) samples were preselected for LOH in the region of p53. We detected 23 p53 mutations within these exons in 22 lung cancers; no p53 mutations were found in normal tissue of the patients. One-half of the mutations were G to T transversions on the nontranscribed strand, consistent with mutagenesis by tobacco smoke. Mutations of C to A on the nontranscribed strand, which would result from G to T mutations on the transcribed strand, were detected only in one sample. Three of 23 mutations were nonsense mutations; to date, nonsense mutations of p53 have not been reported in lung cancer. Mutation of this p53-coding region was detected in 20 of 27 small cell lung cancer samples, representing a 70% occurrence. Mutation of the p53 gene is apparently very frequent in small cell lung cancers. When LOH in the p53 region could be determined, complete concordance occurred between a sample having both a p53 mutation and LOH in the region of p53 (18 of 18 samples). Twelve samples of lung cancer had LOH in the region of p53, but the samples had no detectable p53 mutations, suggesting either alterations outside the known mutational hot spots of p53 or alterations of another unidentified tumor suppressor gene in the region of p53.
Similar articles
- High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H. Wang YC, et al. Cancer Res. 1998 Jan 15;58(2):328-33. Cancer Res. 1998. PMID: 9443413 - High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.
D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R, et al. D'Amico D, et al. Oncogene. 1992 Feb;7(2):339-46. Oncogene. 1992. PMID: 1312696 - Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, et al. Chiba I, et al. Oncogene. 1990 Oct;5(10):1603-10. Oncogene. 1990. PMID: 1979160 - [p53 gene mutations in the human lung carcinoma].
Saito M, Takahashi S, Uesaka Y, Enomoto K. Saito M, et al. Nihon Rinsho. 1996 Feb;54(2):497-502. Nihon Rinsho. 1996. PMID: 8838104 Review. Japanese.
Cited by
- Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.
Hardy-Werbin M, Arpí O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier CH, Arriola E. Hardy-Werbin M, et al. Oncoimmunology. 2017 Nov 27;7(2):e1395125. doi: 10.1080/2162402X.2017.1395125. eCollection 2018. Oncoimmunology. 2017. PMID: 29308329 Free PMC article. - Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.
Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, Krolewski J. Ittmann M, et al. Am J Pathol. 1994 Aug;145(2):287-93. Am J Pathol. 1994. PMID: 8053489 Free PMC article. - Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Byers LA, et al. Cancer Discov. 2012 Sep;2(9):798-811. doi: 10.1158/2159-8290.CD-12-0112. Epub 2012 Sep 6. Cancer Discov. 2012. PMID: 22961666 Free PMC article. - Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.
Hardy-Werbin M, Rocha P, Arpi O, Taus Á, Nonell L, Durán X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier C, Arriola E. Hardy-Werbin M, et al. Oncoimmunology. 2019 Mar 27;8(6):e1593810. doi: 10.1080/2162402X.2019.1593810. eCollection 2019. Oncoimmunology. 2019. PMID: 31069160 Free PMC article. - Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array.
Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage S, Jen J, Sidransky D. Ahrendt SA, et al. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7382-7. doi: 10.1073/pnas.96.13.7382. Proc Natl Acad Sci U S A. 1999. PMID: 10377423 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous